[1] REICHERT J M. Which are the antibodies to watch in 2013 . Mabs, 2013, 5 (1):1-4. [2] GOLDENBERG M M. Pharmaceutical approval update . P T, 2013,38(5):246-258. [3] GOLDENBERG MM. Pharmaceutical approval update . P T, 2014,39(1):37-39. [4] REICHERT J M. Antibodies to watch in 2013:Mid-year update . Mabs, 2013, 5 (4):513-517. [5] PEREZ HL, CARDARELLI P M, Deshpande S, et al. Antibody-drug conjugates:current status and future directions . Drug Discov Today, 2014,19(7):869-881.[6] FDA. FDA news release:Pfizer voluntarily withdraws cancer treatment Mylotarg from U. S. market (http://www. fda. gov/%20NewsEvents/Newsroom/PressAnnouncements/ucm216448. htm). 2010. [7] FDA. FDA news release:FDA approves Adcetris to treat two types of lymphoma. 2011. http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm268781. htm. 2011. [8] VERMA S, MILES D, GIANNI L, et al. Trastuzumab entansine for HER2-positive advanced breast cancer . N Engl J Med, 2012, 367:1783-1791. [9] JACKSON D, ATKINSON J, GUEVARA C I, et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates . PLoS One, 2014,9(1):e83865. ZHU J W. Mammalian cell protein expression for biopharmaceutical production . Biotechnol Adv, 2012, 30(5):1158-1170. GAO K, WANG J Z. The biopharmaceutical industry in China:history and future perspectives . Front Med, 2012, 6(2):101-111 EUROPEAN MEDICINE EVALUATION AGENCY. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:non-clinical and clinical issues. 2006:4. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. (EMEA/CHMP/BMWP/ 31329/2005). http://www.docin.com/p-534854471.htm. WHO Expert Committee on Biological Standardization Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009:10-16. http://www. who. int/biologicals/publications/trs/areas/biological_therapeutics/Guidelines_Biotherapeutic_products_FINAL_HK_IK_12_June. pdf SHAH V P, Crommelin D J. Regulatory framework for biosimilars . Pharm Biotechnol. 2013, 31(8):247-254 FDA. FDA news release:FDA issues drraft guidance on biosimilar product development. 2012. http://www. fda. gov/newsevents/newsroom/pressannouncements/ucm291232. htm. MULLARD A. Can next-generation antibodies offset biosimilar competition . Nat Rev Drug Discov, 2012, 11 (6):426-428. TAN Q, GUO Q, FANG C, et al. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products . MAbs, 2012, 4(6):761-774. Anurag S. R, Robin M. Quality by Design for Biopharmaceuticals-Principles and Case Studies . Weinheim:Wiley Interscience, 2009. XU Z, LI J, ZHOU J X, et al. Process development for robust removal of aggregates using cation exchange chromatography in monoclonal antibody purification with implement of quality by design . Preparative Biochemistry and Biotechnology, 2012, 42(2):183-202. WANG L, GAO K, FAN W H, et al. Preparation of national standard substance of CHO cell DNA . Chin Pharm J(中国药学杂志), 2013, 48(1):68-72. BI H, FAN W H, HAN C M, et al. Study on quality control methods and standards of recombinant humanized rabbit anti-VEGF mAb . Chin J Pharm Anal(药物分析杂志), 2012, 32(6):1054-1058. ZHANG F, LIU C Y,GUO W, et al. DiFi cell proliferation inhibition test for biological potenty detection of anti-EGFR monoclonal antibody , Collection of papers of 2012 China Pharmaceutical Conference and the 12th China Pharmacist Week, 2012. TAO L, RAO C M, WANG L, et al. Development of a method for quality control of humanized monoclonal antibody against epithelial growth factor receptor . Chin J Biol(中国生物杂志), 2013,26(1):72-75. WANG L, RAO C M,LI Y H, et al. Development of A Method for Determination of Biological Activity of Vascular Endothelial Growth Factor Trap . Chin J Biol(中国生物杂志), 2009, 22 (9):895-906. DUAN X T, DAI L P, CHEN S C, et al. Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis . J Chromatogr A, 2012, 1251(17):63-73. LI M Z, HAN W D, XING G H, et al. Research of N Terminal Sequencing Methods for Monoclonal Antibody Pharmaceuticals Blocked by Pyroglutamic Acid . Chin Biotechnol J(生物化学杂志), 2013, 33 (8):73-80. LI X J, WANG F Q, XU W, et al. Disulfide bond assignment of an IgG1 monoclonal antibody by LC–MS with post-column partial reduction . Analy Biochem, 2013, 436(2):93-100. YUAN L, ARNOLD M E, AUBRY A F, et al. Simple and efficient digestion of a monoclonal antibody in serum using pellet digestion:comparison with traditional digestion methods in LC-MS/MS bioanalysis . Bioanalysis, 2012, 4(24):2887-96. CHUNG C H, MIRAKHUR B, CHAN E, et al. Cetuximab Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose. N Eng J Med, 2008, 358:1109-1117. TAO L, RAO C M, Gao K, et al. Effect of theoligosaccharides IgG1 on its structure and function . Chin J Pharm Anal(药物分析杂志), 2011,31(11):2095-2098. ZHANG W J, HAN H H, BAI H H, et al. A Highly Efficient and Visualized Method for Glycan Enrichment by Self-Assembling Pyrene Derivative Functionalized Free Graphene Oxide . Anal Chem, 2013, 85 (5):2703-2709. ZHANG F, GUO W, ZHANG J, et al. Research on factors affecting Dot-blot detection of residual host cell DNA in therapeutic monoclonal antibodies . Chin J Pharm Anal(药物分析杂志), 2012,32(1):111-119. GAO K, REN Y M, Wang L, et al. Points to consider for the general monograph of products prepared by recombinant DNA technology in Chinese Pharmacopeia . Chin Biotechnol J(生物化学杂志), 2014, 34 (5):107-115. GAO K, XU Z K, REN Y M, et al. Points to consider for the general monograph of monoclonal antibody based biotherapeutics in Chinese Pharamacopeia . Chin Biotechnol J(生物化学杂志), 2014, 34 (1):137-134.